Navigation Links
DURECT Corporation Announces Fourth Quarter and Year End 2010 Financial Results
Date:3/2/2011

h this product represents a modest revenue opportunity for DURECT by itself, the SABER technology is the basis for our POSIDUR program currently in a pivotal Phase III clinical trial as well as for multiple on-going feasibility projects seeking to deliver proteins and peptides for periods of up to one month from a single injection.


  • Financial Guidance.  Our net cash consumption is heavily influenced by the timing and structure of new corporate collaborations, as well as the achievement of milestones under existing collaborations.  While we anticipate entering into new collaborations in 2011 and beyond, assuming no new collaborations, no milestone or royalty payments and aggressive funding of our R&D programs, many of which are in clinical development, we anticipate our net cash consumption in 2011 will be approximately $23-27 million.


  • Business Development Activities.  We have multiple programs that may potentially be partnered over the next 12-18 months.  These include TRANSDUR-Sufentanil worldwide rights, POSIDUR for Japan, ORADUR-ADHD, as well as various internal programs which we have not described publicly in detail.Earnings Conference CallA live audio webcast of a conference call to discuss 2010 results will be broadcast over the internet at 4:30 p.m. Eastern Time on March 2 and is available by accessing DURECT's homepage at www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

    About DURECT CorporationDURECT is a specialty pharmaceutical compan
    '/>"/>


  • SOURCE DURECT Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. DURECTs Collaboration With Alpharma Clears HSR Review and Is Effective
    2. DURECT Corporation Announces Third Quarter 2008 Financial Results
    3. DURECT Corporation Invites You to Join its Third Quarter 2010 Earnings Conference Call
    4. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
    5. Pharmos Corporation Reports 2008 Second Quarter Results
    6. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
    7. Genaera Corporation Announces Second Quarter Financial Results
    8. MannKind Corporation Reports Second Quarter Financial Results
    9. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
    10. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
    11. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/15/2014)... Sept. 15, 2014 EnGeneIC, Ltd. ... the treatment of cancer through the targeted delivery ... that, together with the Asbestos Disease Research Institute ... New South Wales (NSW) Premier,s Award for Excellence ... are the hospitals that will be involved in ...
    (Date:9/15/2014)... State University have developed a technique for controlling the ... voltages, opening the door to a new generation of ... hinges on the fact that the oxide "skin" of ... acts as a surfactant, lowering the surface tension ... researchers used a liquid metal alloy of gallium and ...
    (Date:9/15/2014)... of carbon nanotubes is neat, but Rice University scientists are ... in new fibers created at Rice line up like a ... Angel Mart and his colleagues. , The tricky bit, according ... the journal ACS Nano , is keeping the densely ... , Left to their own devices, carbon nanotubes form clumps ...
    (Date:9/15/2014)... MORRISVILLE, NC (PRWEB) September 15, 2014 ... newly developed deep imaging OCT system for the optical ... , The EnvisuTM S4410 SDOCT for Contact ... measurements for standard and high complexity contact lens, IOL ... allows imaging of a complete contact lens immersed in ...
    Breaking Biology Technology:EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 2EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 3Researchers control surface tension to manipulate liquid metals 2Rice rolls 'neat' nanotube fibers 2Rice rolls 'neat' nanotube fibers 3Bioptigen Introduces Deep Imaging OCT System for Contact Lens Metrology 2
    ... High-quality plasmid DNA for all demanding ... Jeff Braman ,Stratagene , A new ... and reliably isolate,high-purity plasmid DNA. The convenient ... flow columns, and alcohol precipitations, while,easily accommodating ...
    ... versatile kit for site-directed mutagenesis of,large plasmids ... Holly Hogrefe ,Jeff Braman ,Stratagene , ... efficiencies exceeding 80%. We have created a ... The QuikChange XL,site-directed mutagenesis ...
    ... accurate using the Quantos cell,proliferation assay kit ... LLC , The Quantos cell proliferation ... the number of cells present in,various tissue culture ... well the kit,performed compared to another commercial fluorescence-based ...
    Cached Biology Technology:A Simple and Rapid Technique to Purify High-Quality Midiprep DNA 2A Simple and Rapid Technique to Purify High-Quality Midiprep DNA 3A Simple and Rapid Technique to Purify High-Quality Midiprep DNA 4High-Efficiency Site-Directed Mutagenesis of Large Plasmid Vectors 2High-Efficiency Site-Directed Mutagenesis of Large Plasmid Vectors 3High-Efficiency Site-Directed Mutagenesis of Large Plasmid Vectors 4Cell Proliferation Kit Outperforms the Competition in the Range of Cells,Typically Counted 2Cell Proliferation Kit Outperforms the Competition in the Range of Cells,Typically Counted 3Cell Proliferation Kit Outperforms the Competition in the Range of Cells,Typically Counted 4
    (Date:9/15/2014)... digestion to disease resistance. Despite the fact that tropical ... planet, more is known about belly-button bacteria than bacteria ... working on Panama,s Barro Colorado Island discovered that small ... more than 400 different kinds of bacteria. The combined ... different kinds. , Bacteria in tropical forests may also ...
    (Date:9/15/2014)... indicates that lowland tapir populations may continue to drop ... Researchers from the Office National de la Chasse et ... Diego Zoo Global reviewed data retrieved from camera traps ... years and compared this data to current harvest rates ... hunting tapirs in French Guiana," said Matthias Tobler, a ...
    (Date:9/15/2014)... epilepsy drug to a morphine regimen can result in ... combination can reduce the dosage of the opioid needed ... researchers at Indiana University. , The result could bring ... difficult-to-treat condition often felt in the arms and legs ... a huge unmet need for better treatments for neuropathic ...
    Breaking Biology News(10 mins):Smithsonian scientists discover tropical tree microbiome in Panama 2IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2
    ... has made significant inroads into uncovering the genetic basis ... with overall obesity and 13 that affect fat distribution. ... a million participants, the largest genetic investigation of human ... (Genetic Investigation of ANthropometric Traits) consortium which consists ...
    ... may be on the way for millions of people on ... bugs. Scientists have reported a key advance in efforts to ... as a major nuisance to homeowners and a devastating pest ... a fungus that infects a common weed and found that ...
    ... ovarian cancer has shown single agent activity with durable disease ... international research group has reported. Dr Ursula Matulonis ... of the single-agent trial of the drug, called MLN8237, in ... for Medical Oncology (ESMO). MLN8237 selectively inhibits ...
    Cached Biology News:Studies provide new insights into the genetics of obesity and fat distribution 2Studies provide new insights into the genetics of obesity and fat distribution 3Progress toward first commercial repellent for East Coast's stinker 2Investigational ovarian cancer drug shows promise against platinum resistant disease 2